Serentis Expands Series A

Serentis Inc., a Cambridge, UK dermatology drug startup formed by former Arakis Ltd. executives, has raised Gbp5.3 million in additional Series A funding. It had held a Gbp10 million first close last year. Backers include MVM Life Science Partners, Apposite Capital, East Hill and Novo AS.


Serentis, a privately owned biopharmaceutical company, announced today that it has closed a Gbp10 million ($20 million) financing, expanding the total of its Series A financing to Gbp15.3 million ($30 million). The funding will be used to advance and expand Serentis' dermatology pipeline.


In July 2007, Serentis announced a